1.
Correlation between miR-148 and miR-155 expression with clinicopathological characteristics of advance stage NSCLC patients
| Characteristic | miR-34 | miR-222 | miR-148 | miR-155 | |||||||
| Median (Min.: Maks.) | P | Median (Min.; Maks.) | P | Median (Min.; Maks.) | P | Median (Min.; Maks.) | P | ||||
| Comparison was determined by Wilcoxon rank sum test or Kruskal-Walls H rank sum test. P value < 0.05 was considered as statistically significant. PS: performance status; epidermal growth factor receptor. | |||||||||||
| Gender (n=52) |
1.125 (0.06; 109.14) |
0.968 | 5.65 (0.04; 5, 789.38) |
0.558 | 15.66 (0.11; 7, 214.42) |
0.832 | 3.66 (0.06; 660.16) |
0.912 | |||
| Male (n=37) | 1.43 0.06; 09.14) |
16.87 (0.04; 12, 914.16) |
14.09 (0.11; 3, 508.57) |
6.758 (0.06; 426.58) |
|||||||
| Female (n=15) | 0.97 (0.28; 51.98) |
1.94 (0.07; 15, 789.38) |
20.63 (0.35; 7, 214.42) |
1.307 (0.07; 660.16) |
|||||||
| Age category (n=52) |
1.13 (0.06; 109.14) |
0.344 | 5.65 (0.04; 15, 789.38) |
0.665 | 15.66 (0.11; 7, 214.42) |
0.562 | 3.657 (0.06; 660.16) |
0.685 | |||
| > 60 years (n=20) | 1.75 (0.28; 51.98) |
17.41 (0.09; 15, 789.38) |
17.91 (0.43; 7, 214.42) |
7.073 (0.10; 660.16) |
|||||||
| 40-60 years (n=28) | 0.91 (0.06; 109.14) |
2.44 (0.04; 9, 519.48) |
12.01 (0.35; 3, 251.00) |
1.37 (0.06; 145.68) |
|||||||
| < 40 years (n=4) | 2.36 (0.15; 27.10) |
81.74 (0.05; 176.89) |
163.19 (0.11; 664.75) |
4.531 (0.07; 82.52) |
|||||||
| Smoking (n=52) |
1.13 (0.06; 109.14) |
0.435 | 5.65 (0.04; 15, 789.38) |
0.847 | 15.66 (0.11; 7, 214.42) |
0.457 | 3.66 (0.06; 660.16) |
0.614 | |||
| Yes (n=24) | 1.29 (0.06; 44.94) |
5.65 (0.05; 250.15) |
13.53 (0.11; 883.24) |
1.33 (0.07; 219.29) |
|||||||
| No (n=28) | 1.10 (0.28; 109.14) |
8.45 (0.04; 15789.34) |
23.65 (0.35; 7, 214.42) |
7.07 (0.06; 660.16) |
|||||||
| PS (n=52) | 1.13 (0.06; 109.14) |
0.131 | 5.65 (0.04; 15, 789.38) |
0.018 | 15.66 (0.11; 7, 214.42) |
0.049 | 3.66 (0.06; 660.16) |
0.176 | |||
| PS 3-4 (n=14) | 3.46 (0.45; 51.98) |
67.60 (0.30; 15, 789.38) |
70.39 (0.65; 7, 214.42) |
9.99 (0.12; 660.16) |
|||||||
| PS 2 (n=19) | 0.85 (0.06; 51.27) |
1.94 (0.09; 12, 914.16) |
12.97 (0.43; 3, 508.57) |
1.25 (0.10; 426.58) |
|||||||
| Clinical stage (n=52) |
1.13 (0.06; 109.14) |
0.842 | 5.65 (0.04; 15, 789.38) |
0.652 | 15.66 (0.11; 7, 214.42) |
0.887 | 3.66 (0.06; 660.16) |
0.610 | |||
| Ⅳb (n=28) | 0.85 (0.06; 51.27) |
3.29 (0.04; 12, 914.16) |
17.23 (0.43; 3, 508.57) |
1.31 (0.06; 426.58) |
|||||||
| Ⅳa (n=21) | 1.58 (0.15; 51.98) |
36.65 (0.05; 15, 789.38) |
23.12 (0.11; 7, 214.42) |
14.51 (0.07; 660.16) |
|||||||
| Ⅲb (n=3) | 1.96 (0.28; 109.14) |
0.56 (0.23; 521.55) |
4.19 (0.49; 444.69) |
0.43 (0.22; 137.88) |
|||||||
| Tumor status (n=52) |
1.13 (0.06; 109.14) |
0.607 | 5.65 (0.04; 15, 789.38) |
0.948 | 15.66 (0.11; 7, 214.42) |
0.570 | 3.66 (0.06; 660.16) |
0.782 | |||
| T4 (n=35) |
1.10 (0.06; 51.98) |
2.94 (0.04; 15, 789.38) |
11.69 (0.11; 7, 214.42) |
1.25 (0.06; 660.16) |
|||||||
| T3 (n=7) |
0.77 (0.20; 109.14) |
1.94 (0.07; 521.55) |
2.86 (0.35; 444.69) |
1.31 (0.07; 137.82) |
|||||||
| T2 (n=4) |
3.30 (0.73; 9.58 |
23.39 (0.30; 47.73) |
69.37 (1.07; 251.89) |
18.53 (0.18; 50.10) |
|||||||
| T1 (n=6) |
3.48 (0.28; 44.94) |
11.94 (0.18; 176.89) |
91.31 (0.59; 503.79) |
17.26 (0.14; 82.52) |
|||||||
| Nodule status (n=52) |
1.13 (0.06; 109.14) |
0.625 | 5.65 (0.04; 15, 789.38) |
0.742 | 15.66 (0.11; 7, 214.42) |
0.495 | 3.66 (0.06; 660.16) |
0.601 | |||
| N3 (n=13) |
0.85 (0.20; 109.14) |
2.94 (0.07; 12, 914.16) |
11.06 (0.35; 3, 508.57) |
1.31 (0.07; 426.58) |
|||||||
| N2 (n=36) |
1.29 (0.06; 51.98) |
5.65 (0.04; 15, 789.38) |
16.34 (0.11; 7, 214.42) |
3.666 (0.06; 660.16) |
|||||||
| N0 (n=3) |
2.91 (1.10; 4.56) |
67.49 (1.81; 176.89) |
325.54 (4.95; 503.79) |
51.86 (1.00; 82.52) |
|||||||
| Metastasis status (n=52) |
1.13 (0.06; 109.14) |
0.842 | 5.65 (0.04; 15, 789.38) |
0.652 | 15.66 (0.11; 7, 214.42) |
0.887 | 3.66 (0.06; 660.16) |
0.610 | |||
| M1b (n=29) | 0.85 (0.06; 51.27) |
3.29 (0.04; 12, 914.16) |
17.23 (0.43; 3, 508.57) |
1.31 (0.06; 426.58) |
|||||||
| M1a (n=20) | 1.58 (0.15; 51.98) |
36.65 (0.05; 15, 789.38) |
23.12 (0.11; 7, 214.42) |
14.51 (0.07; 660.16) |
|||||||
| M0 (n=3) |
1.96 (0.28; 109.14) |
0.56 (0.23; 521.55) |
4.19 (0.49; 444.69) |
0.43 (0.22; 137.82) |
|||||||
| M1b metastatic type (n=29) |
0.85 (0.06; 51.27) |
0.020 | 3.29 (0.04; 12, 914.16) |
0.383 | 17.23 (0.43; 3, 508.57) |
0.074 | 1.31 (0.06; 426.58) |
0.169 | |||
| Single (n=19) | 0.77 (0.06; 27.10) |
2.94 (0.04; 669.37) |
4.95 (0.43; 664.75) |
1.25 (0.06; 145.68) |
|||||||
| Multiple (n=10) | 3.21 (0.59; 51.27) |
11.94 (0.30; 12, 914.16) |
31.29 (1.07; 3, 508.57) |
8.05 (0.18; 426.58) |
|||||||
| M1b metastatic location (n=29) |
0.85 (0.06; 51.27) |
0.176 | 3.29 (0.04; 12, 914.16) |
0.300 | 17.23 (0.43; 3, 508.57) |
0.295 | 1.31 (0.06; 426.58) |
||||
| Brain (n=6) | 0.70 (0.36; 2.91) |
35.39 (0.30; 669.37) |
19.61 (0.43; 503.79) |
9.55 (0.12; 51.86) |
|||||||
| Liver (n=2) | 0.81 (0.77; 0.85) |
20.25 (0.09; 40.41) |
16.63 (0.67; 32.60) |
5.59 (0.13; 11.06) |
|||||||
| Bone (n=9) | 0.66 (0.06; 9.45) |
1.43 (0.04; 94.79) |
1.97 (0.43; 594.97) |
1.00 (0, 06; 145.68) |
|||||||
| Adrenal gland (n=2) | 13.86 (0.62; 27.10) |
96.80 (30.84; 162.77) |
333.81 (2.86; 666.75) |
8.59 (8.26; 8.92) |
|||||||
| Multiorgan (n=10) | 3.21 (0.59; 51.27) |
11.94 (0.30; 12, 914.16) |
31.29 (1.07; 3, 508.57) |
8.05 (0.18; 426.58) |
|||||||
| Cancer cell type (n=52) |
1.13 (0.06; 109.14) |
0.009 | 5.65 (0.04; 15, 789.38) |
0.113 | 15.66 (0.11; 7, 214.42) |
0.082 | 3.66 (0.06; 660.16) |
||||
| Adenocarcinoma (n=43) |
1.50 (0.15; 109.14) |
16.87 (0.05; 15, 789.38) |
20.63 (0.11; 7, 214.42) |
8.26 (0.07; 660.16) |
|||||||
| Squamous cell carcinoma (n=9) | 0.66 (0.06; 2.16) |
0.89 (0.04; 217.77) |
1.97 (0.53; 190.90) |
0.20 (0.06; 89.06) |
|||||||
| Adenocarcinoma: EGFR mutation status (n=43) | 1.50 (0.15; 109.14) |
0.031 | 16.87 (0.05; 15, 789.38) |
0.064 | 20.63 (0.11; 7, 214.42) |
0.168 | 8.26 (0.07; 660.16) |
||||
| Positive (n=10) | 0.81 (0.15; 4.56) |
1.67 (0.05; 176.89) |
8.57 (0.11; 503.79) |
0.79 (0.07; 82.52) |
|||||||
| Negative/Wild type (n=33) | 2.35 (0.28; 109.14) |
25.58 (0.07; 15, 789.38) |
33.28 (0.35; 7214.42) |
8.20 (0.07; 660.16) |
|||||||
|
EGFR mutation status (n=52) |
1.125 (0.06; 109.14) |
0.153 | 5.65 (0.04; 15, 789.38) |
0.18 | 15.66 (0.11; 7214.42) |
0.335 | 3.66 (0, 06; 660, 16) |
||||
| Positive (n=10) | 0.81 (0.15; 4.56) |
1.67 (0.05; 176.89) |
8.57 (0.11; 503.79) |
0.79 (0.07; 82.52) |
|||||||
| Negative/Wild type (n=42) | 1.58 (0.06; 109.14) |
15.24 (0.04; 15, 789.38) |
17.91 (0.35; 7214.42) |
7.51 (0.06; 660.16) |
|||||||